Reach Us +44-1647-403003
Lactoferricin B Peptide Kills Breast Cancer Cells In Vitro; Potential For Therapy | 52973
ISSN: 1948-5956

Journal of Cancer Science & Therapy
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Lactoferricin B peptide kills breast cancer cells in vitro; potential for therapy

2nd World Congress on Breast Cancer

Ebenezer Chitra, Muhammad Rizdwan Bin Mohd Abd Rahman, Fabian Davamani, Alan Khoo, Munirah Ahmad and Stephen Ambu

International Medical University, Malaysia

ScientificTracks Abstracts: J Cancer Sci Ther

DOI: 10.4172/1948-5956.C1.081

Breast cancer is one of the most common cancers in women and is currently treated by surgery and a combination of chemotherapy and radiotherapy. Lactoferricin B (Lfcin B) is a 25-mer natural peptide obtained from milk protein lactoferrin and is capable of inducing apoptosis in cancer cell lines. The effect of Lfcin B in breast cancer cell lines has not been tested so far. In this study, the effects of Lfcin B peptide was tested on a panel of breast cancer cell lines comprising of MCF 7 (Luminal A type expressing estrogen receptor and progesterone receptor; triple negative), MDA-MB-231 (claudin low type; triple negative), SKBR3 (over-expressing HER2) and MDA-MB-468 (basal type). The mammary epithelial cell line, MCF-10a was used as a normal control. Lfcin B was dissolved in plain medium and the cells were treated with various concentrations of the peptide (100 μg/ml to 300 μg/ml) to study its effect on proliferation, cell migration and apoptosis. Apoptosis was studied by flow cytometry of annexin-PI stained cells and western blot while changes in the gene expression induced by Lfcin B were analyzed by quantitative RT-PCR. Lfcin B peptide induced significantly more apoptosis in all the breast cancer cell lines studied compared to normal breast epithelial cells. The peptide suppressed cell migration in the invasive cell lines MDA-MB-231 and MDA-MB-468. Our studies suggest a potential for Lfcin B to be developed for breast cancer therapy.

Ebenezer Chitra completed her PhD from National Institute of Immunology, Jawaharlal Nehru University, New Delhi, India. She did her Post-doctoral fellowship in National Health Research Institutes, Taiwan working on cell signaling in cancer. Currently, she is a faculty in the School of Medicine in International Medical University. Her research interest is in cancer biology.

Email: [email protected]

Relevant Topics